Skip to main content

Table 2 Frequency of the most common adverse events

From: Adverse events in Chinese human immunodeficiency virus (HIV) patients receiving first line antiretroviral therapy

 BaselineAfter treatment
Adverse EventGrade 1–2Grade 3–4TotalGrade 1–2Grade 3–4Total
Liver function97(20.5%)2(0.4%)99(20.9%)208 (43.9%)20 (4.2%)228 (48.1%)
 ALT31(6.5%)1(0.2%)32(6.8%)181 (38.2%)14 (3.0%)195 (41.1%)
 AST63(13.3%)0(0%)63(13.3%)144 (30.4%)13 (2.7%)157 (33.1%)
 TBIL33(7%)1(0.2%)34(7.2%)17 (3.6%)3 (0.6%)20 (4.2%)
Impaired renal function
 eGFR6(1.3%)1(0.2%)7(1.5%)29 (6.1%)2 (0.4%)31 (6.5%)
Dyslipidemia116(24.4%)7(1.5%)123(25.9%)328 (69.2%)48 (10.1%)376 (79.3%)
 TC31(6.5%)0(0%)31(6.5%)253 (53.4%)8 (1.7%)261 (55.1%)
 TG92(19.4%)3(0.6%)95(20%)265 (55.9%)38 (8.0%)303 (63.9%)
 LDL-c24(5.1%)4(0.8%)28(5.9%)112 (23.6%)13 (2.7%)125 (26.4%)
Skin lesions
 Erythra34(7.2%)1(0.2%)35(7.4%)54 (11.4%)1 (0.2%)55 (11.6%)
Nervous system328(69.2%)25(5.3%)353(74.5%)431 (90.9%)22 (4.6%)453 (95.6%)
 Headache44(9.3%)0(0%)44(9.3%)51 (10.8%)0 (0%)51 (10.8%)
 Insomnia321(67.7%)0(0%)321(67.7%)446 (94.1%)0 (0%)446 (94.1%)
 Anxiety115(24.3%)19(4%)134(28.3%)192 (40.5%)14 (3.0%)206 (43.5%)
 Depression92(19.4%)12(2.5%)104(21.9%)176 (37.1%)14 (3.0%)190 (40.1%)
Total367(77.4%)36(7.6%)403(85.0%)387 (81.7%)85 (17.9%)472 (99.6%)